See the DrugPatentWatch profile for ambien
Ambien, the brand name for zolpidem, has been available on the market since its initial approval by the U.S. Food and Drug Administration (FDA) in 1992 [1].
When does Ambien's patent expire?
The original patents for Ambien have long since expired. Zolpidem was first patented in the 1980s. The primary patents protecting the original Ambien formulation by Sanofi expired decades ago, allowing for the introduction of generic versions of zolpidem [2].
What are the generic versions of Ambien called?
The generic version of Ambien is known as zolpidem tartrate [3]. These generic versions became available after the expiration of the brand-name drug's patents.
Who manufactures generic zolpidem?
Multiple pharmaceutical companies manufacture generic zolpidem tartrate. These include companies like Teva Pharmaceuticals, Mylan (now Viatris), and Sun Pharmaceutical Industries, among others [4].
How does zolpidem work?
Zolpidem is a sedative-hypnotic medication that works by enhancing the effect of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain [5]. GABA reduces nerve activity in the brain, leading to calmness and sleep. Zolpidem binds to specific GABA receptors, which amplifies this inhibitory effect, helping to induce sleep.
What are the side effects of Ambien (zolpidem)?
Common side effects associated with zolpidem use include drowsiness, dizziness, lightheadedness, and a metallic or altered taste in the mouth [6]. More serious side effects can include complex sleep behaviors, such as sleepwalking or sleep-driving, amnesia, hallucinations, and respiratory depression, especially when combined with alcohol or other central nervous system depressants [7].
Why might Ambien be prescribed?
Ambien is primarily prescribed for the short-term treatment of insomnia characterized by difficulties with falling asleep [8]. It is intended for use when a person's sleep problems are significantly impacting their daily functioning.
What are the risks of taking zolpidem long-term?
Long-term use of zolpidem may lead to tolerance, where higher doses are needed to achieve the same effect, and dependence, resulting in withdrawal symptoms if the medication is stopped abruptly [9]. There are also concerns about potential cognitive impairment and an increased risk of falls, particularly in older adults, with prolonged use.
What are the alternatives to Ambien for insomnia?
Alternatives to zolpidem include other prescription sleep medications, such as eszopiclone (Lunesta) and zaleplon (Sonata), as well as non-benzodiazepine receptor agonists and certain antidepressants with sedative properties [10]. Non-pharmacological approaches, such as cognitive behavioral therapy for insomnia (CBT-I), are also highly recommended as first-line treatments for chronic insomnia [11].
How is Ambien regulated?
In the United States, zolpidem is classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA) due to its potential for abuse and dependence [12]. This classification imposes certain prescribing and dispensing restrictions.
How does zolpidem's patent history affect its availability and cost?
The expiration of zolpidem's patents paved the way for generic competition, which significantly increased the drug's availability and reduced its cost for consumers [2]. Before patent expiration, brand-name Ambien was considerably more expensive.
Sources:
1. U.S. Food and Drug Administration (FDA) approvals database. (Information based on historical FDA approval dates for zolpidem).
2. DrugPatentWatch.com. (Historical patent data for zolpidem).
3. U.S. National Library of Medicine. (Drug information for zolpidem tartrate).
4. Pharmaceutical company product listings and regulatory filings.
5. American Society of Health-System Pharmacists. (AHFS Drug Information).
6. Mayo Clinic. (Patient information on zolpidem).
7. FDA.gov. (Safety information and warnings regarding zolpidem).
8. Prescribing Information for Ambien (zolpidem tartrate).
9. National Institute on Drug Abuse (NIDA). (Information on prescription drug abuse).
10. National Sleep Foundation. (Information on insomnia treatments).
11. American Academy of Sleep Medicine. (Guidelines for insomnia treatment).
12. U.S. Drug Enforcement Administration (DEA). (Controlled substance schedules).